金币
UID4705
帖子
主题
积分4330
注册时间2011-10-27
最后登录1970-1-1
听众
性别保密
|
发表于 2014-9-24 16:40:12
|
显示全部楼层
大呆子 发表于 2014-9-24 16:26
请出示RCT证据吧
你这个RCT方案能否公布出来大家看看?
文献我都贴出来了,两个,一个是中华医学会,这个分量不够,所以还有内科年鉴,我把原文贴上:
Oseltamivir Compared With the Chinese Traditional TherapyMaxingshigan–Yinqiaosan in the Treatment of H1N1 Influenza
A Randomized Trial
ChenWang, MD, PhD; Bin Cao, MD; Qing-Quan Liu, MD; Zhi-Qiang Zou, MD; Zong-AnLiang, MD; Li Gu, MD; Jian-Ping Dong, MD;
Li-RongLiang, MD; Xing-Wang Li, MD; Ke Hu, MD; Xue-Song He, MD; Yan-Hua Sun,MD; Yu An, MD; Ting Yang, MD; Zhi-Xin Cao, MD;
Yan-MeiGuo, MD; Xian-Min Wen, MD; Yu-Guang Wang, MD; Ya-Ling Liu, MD; and Liang-DuoJiang, MD
Background:Observational studiesfrom Asia suggest that maxingshigan–yinqiaosanmay be effective in the treatment of acute H1N1 influenza.
Objective:To compare the efficacyand safety of oseltamivir and maxingshigan–yinqiaosan in treating uncomplicatedH1N1 influenza.
Designrospective,nonblinded, randomized, controlled trial.(ClinicalTrials.gov registrationnumber: NCT00935194)
Setting:Eleven hospitals from 4provinces in China.
Patients:410 young adults aged 15 to 59 years with laboratoryconfirmedH1N1 influenza.
Intervention:Oseltamivir, 75 mgtwice daily; maxingshigan–yinqiaosan decoction (composed of 12 Chinese herbalmedicines,including honey-fried Herba Ephedrae), 200 mL 4 times daily;oseltamivir plus maxingshigan–yinqiaosan; or no intervention (control).Interventionsand control were given for 5 days.
Measurementsrimary outcome wastime to fever resolution.Secondary outcomes included symptom scores and viralshedding determined by using real-time reverse transcriptase polymerase chainreaction.
Results:Significant reductionsin the estimated median time to fever resolution compared with the controlgroup (26.0 hours [95% CI, 24.0 to 33.0 hours]) were seen with oseltamivir (34%[95% CI, 20% to 46%]; P _ 0.001), maxingshigan–yinqiaosan (37% [CI, 23%to 49%]; P _ 0.001), and oseltamivir plus maxingshigan–yinqiaosan(47% [CI, 35% to 56%]; P _ 0.001). Time to fever resolution was reducedby 19% (CI, 0.3% to 34%; P _ 0.05) with oseltamivir plus maxingshigan–yinqiaosancompared with oseltamivir.The interventions and control did not differ in termsof decrease in symptom scores (P _ 0.38). Two patients who receivedmaxingshigan–yinqiaosan reported nausea and vomiting.
Limitationsarticipants were youngand had mild H1N1 influenza virus infection. Missing viral data precludeddefinitive conclusionsabout viral shedding.
Conclusion:Oseltamivir andmaxingshigan–yinqiaosan, alone and in combination, reduced time to feverresolution in patients with H1N1 influenza virus infection. These data suggestthat maxingshigan– yinqiaosan may be used as an alternative treatment of H1N1 influenzavirus infection.
PrimaryFunding Source: Beijing Science and Technology Project and Beijing Nova Program. |
|